TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Authors
Agata Nawrot
Giuseppe Curigliano (ORCID: https://orcid.org/0000-0003-1781-2518)
Sherene Loi (ORCID: https://orcid.org/0000-0001-6137-9171)
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Agata Nawrot, Giuseppe Curigliano, Sherene Loi, Tina Hovey et al.
Citations
15 citations
Journal
Therapeutic Advances in Medical Oncology
Topics
HER2/EGFR in Cancer Research
Field-Weighted Citation Impact (FWCI)
15.68
article
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer
Agata Nawrot, Giuseppe Curigliano, Sherene Loi, Tina Hovey, Massimo Cristofanilli, Shigehira Saji, Petra Vuković, Mafalda Oliveira, Stephanie L. Graff, Peter Schmid, David W. Cescon, Joyce O’Shaughnessy, Shusen Wang, KY Tse, Seock-Ah Im
article en
15 citations
Abstract
No abstract available for this paper.
Publication Tag
Therapeutic Advances in Medical OncologyVol. 17
Institutions
AstraZeneca (United Kingdom) (GB), Fukushima Medical University (JP), Sun Yat-sen University (CN), Queen Mary University of London (GB), University of Milan (IT), Cornell University (US), Brown University (US), Texas Oncology (US), Peter MacCallum Cancer Centre (AU), Princess Margaret Cancer Centre (CA), Seoul National University Hospital (KR), Vall d'Hebron Hospital Universitari (ES), AstraZeneca (Poland) (PL), Sun Yat-sen University Cancer Center (CN), AstraZeneca (United States) (US), Weill Cornell Medicine (US), Vall d'Hebron Institute of Oncology (ES), European Institute of Oncology (IT)